Is Labcorp (LH) a risky stock?
As of July 21, 2026, Clavix grades Labcorp (LH) C+ for risk, a composite score of 72 out of 100 on an A+ to F scale, which puts LH in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind LH's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how LH scores on each, as of July 21, 2026.
What's moving LH's risk right now
Company-specific signals Clavix flags behind LH's current grade, drawn from recent news and filings as of July 21, 2026.
Labcorp agreed to pay $14.5 million to settle False Claims Act claims tied to how it billed Medicare for urine drug tests. The deal clears one legal issue but signals ongoing government scrutiny of its billing practices, which could push compliance costs higher.
Labcorp was profiled alongside Charles River, Eurofins, and Evotec in an industry report on cell-based assay services for preclinical rating. The report points to growing demand in Asia-Pacific and Europe and areas like rare-disease models and single-cell services.
What a C+ grade means
On the Clavix A+ to F scale, LH's composite of 72 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell LH or any security. Grades are risk indicators, not predictions of return. Data may be delayed.